Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 6, 2014, Pages 1285-1293

  Daher Abdi, Z ^a   Lavau Denes, S ^b   Premaud A ^a   Urien, S ^c   Sauvage, F L ^a,b   Martin, J ^b   Leobon, S ^b   Marquet, P ^a,b   Tubiana Mathieu, N ^b   Rousseau, A ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Capecitabine; Elderly; Pharmacokinetics; Response

Indexed keywords

CAPECITABINE; DRUG METABOLITE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COLORECTAL CANCER; COMPARTMENT MODEL; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG ELIMINATION; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEMALE; GERIATRIC PATIENT; HAND FOOT SYNDROME; HUMAN; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VERY ELDERLY; VOMITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE;

EID: 84903819474     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2466-0     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60(5):277-300
2. Wydra J, Kruszewski W, Jasiński W, Szajewski M, Ciesielski M, Szefel J et al (2013) Is age a risk factor of postoperative complications in colorectal cancer? Pol Przegl Chir 85:491-495
3. Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-Marty C et al (2007) Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 8:1101-1115 (Pubitemid 350182967)
4. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067 (Pubitemid 30035956)
5. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ et al (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383-1389 (Pubitemid 46606420)
6. Woodhouse KW (1994) Pharmacokinetics of drugs in the elderly. J R Soc Med 87:2-4
7. Turnheim K (2003) When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 38:843-853
8. Twelves C (2001) Vision of the future: capecitabine. Oncologist 6:35-39
9. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281 (Pubitemid 28342121)
10. Gieschke R, Burger H-U, Reigner B, Blesch KS, Steimer J-L (2003) Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 55:252-263 (Pubitemid 36390755)
11. Judson IR, Beale PJ, Trigo JM, Aherne W, Crompton T, Jones D et al (1999) A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs 17:49-56 (Pubitemid 29452747)
12. Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85-104 (Pubitemid 32242792)
13. Louie SG, Ely B, Lenz H-J, Albain KS, Gotay C, Coleman D et al (2013) Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). Br J Cancer 109:1744-1749
14. Gieschke R, Reigner B, Blesch KS, Steimer JL (2002) Population pharmacokinetic analysis of the major metabolites of capecitabine. J Pharmacokinet Pharmacodyn 29:25-47 (Pubitemid 34831931)
15. Urien S, Rezaí K, Lokiec F (2005) Pharmacokinetic modelling of 5-FU production from capecitabine-a population study in 40 adult patients with metastatic cancer. J Pharmacokinet Pharmacodyn 32:817-833 (Pubitemid 41772359)
16. Grande C, Quintero G, Candamio S, París Bouzas L, Villanueva MJ, Campos B et al (2013) Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer. J Geriatr Oncol 4:114-121
17. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14:1077-1085
18. Freedman RA, Pitcher B, Keating NL, Ballman KV, Mandelblatt J, Kornblith AB et al (2013) Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Res Treat 139:607-616
19. Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi M-C, Milano G et al (2008) PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther 83:829-839 (Pubitemid 351704912)
20. Beal SL, Sheiner LB, Boeckmann A, Bauer RJ (1998) NONMEM User's Guide; NONMEM project group. University of California, San Francisco
21. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
22. Etienne MC, Chatelut E, Pivot X, Lavit M, Pujol A, Canal P et al (1998) Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer 34:92-97 (Pubitemid 28123387)
23. Parke J, Holford NH, Charles BG (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 59:19-29 (Pubitemid 29125558)
24. Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, Féty-Deporte R et al (2000) Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther 68:270-279
25. Fety R, Rolland F, Barberi-Heyob M, Hardoin A, Campion L, Conroy T et al (1998) Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinoma. Clin Cancer Res 4:2039-2045 (Pubitemid 28415645)
26. Poole C, Gardiner J, Twelves C, Johnston P, Harper P, Cassidy J et al (2002) Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 49:225-234 (Pubitemid 34185596)
27. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 7:485-493 (Pubitemid 29075232)
28. Abushullaih S, Saad ED, Munsell M, Hoff PM (2002) Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 20:3-10 (Pubitemid 34151055)
29. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT et al (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196